drugset / Trial / NCT04450407

A Study of LY3209590 in Participants With Type 1 Diabetes

NCT04450407

Phase 2 Completed 266 enrolled Eli Lilly and Company
RandomizedParallel-groupOpen-labelTreatment

Summary

The reason for this study is to see if the study drug LY3209590 is safe and effective in participants with type 1 diabetes.

Timeline

Start
2020-07-06
Primary completion
2021-10-01
Completion
2021-10-01

Drugs

EvaluationDrugModalityDoseRoute
Subject Insulin Efsitora Alfa Protein / enzyme biologic Subcutaneous
Comparator insulin degludec Protein / enzyme biologic Subcutaneous